Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DNLI
DNLI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNLI News
REGENXBIO Faces FDA Challenges for Gene Therapy Approval
5d ago
Newsfilter
REGENXBIO's RGX-121 BLA Accepted by FDA Under Accelerated Approval Pathway
5d ago
Benzinga
Denali Therapeutics Advances in Hunter Syndrome Treatment
Feb 05 2026
Newsfilter
Denali Therapeutics Presents Clinical Data at WORLDSymposium 2026
Jan 29 2026
Yahoo Finance
Denali Therapeutics (DNLI) Offers Covered Call with 2.60% Potential Return
Jan 20 2026
NASDAQ.COM
Denali Therapeutics Advances Tividenofusp Alfa with FDA Priority Review for Hunter Syndrome
Dec 30 2025
Globenewswire
Denali Therapeutics Advances Tividenofusp Alfa with Promising Phase 1/2 Results for Hunter Syndrome
Dec 30 2025
Newsfilter
Denali Therapeutics Prices Public Offering at $200 Million
Dec 10 2025
Newsfilter
Denali Therapeutics Prices Public Offering at $17.50 per Share, Raising $200 Million
Dec 10 2025
Globenewswire
Denali Therapeutics Reveals Pricing for Public Offering of Common Stock and Pre-Funded Warrants
Dec 10 2025
Yahoo Finance
Denali Therapeutics Plans $200 Million Stock Offering
Dec 09 2025
Globenewswire
Denali Therapeutics Plans $200 Million Public Offering of Common Stock
Dec 09 2025
Newsfilter
Denali Experiences Slight Delay as FDA Pauses Initiation of Rare Disease Trial
Dec 05 2025
Benzinga
Denali Secures $275 Million Funding Agreement with Royalty Pharma
Dec 05 2025
NASDAQ.COM
Denali and Royalty Pharma Sign $275 Million Royalty Financing Deal
Dec 04 2025
NASDAQ.COM
Royalty Pharma Secures $275M Synthetic Royalty Agreement with Denali for Tividenofusp Alfa
Dec 04 2025
Globenewswire
Show More News
